ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Rating of “Buy” from Brokerages

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have been assigned a consensus recommendation of “Buy” from the ten brokerages that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $97.2857.

ANIP has been the subject of a number of research reports. HC Wainwright upped their price objective on ANI Pharmaceuticals from $93.00 to $121.00 and gave the company a “buy” rating in a research report on Wednesday, September 17th. Truist Financial upped their price target on ANI Pharmaceuticals from $65.00 to $77.00 and gave the stock a “hold” rating in a research report on Monday, August 11th. Guggenheim upped their price target on ANI Pharmaceuticals from $86.00 to $114.00 and gave the stock a “buy” rating in a research report on Monday, September 8th. JPMorgan Chase & Co. upped their price target on ANI Pharmaceuticals from $95.00 to $115.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 24th. Finally, Piper Sandler restated an “overweight” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Friday, August 8th.

ANI Pharmaceuticals Stock Up 0.6%

ANI Pharmaceuticals stock opened at $89.64 on Friday. The stock has a market cap of $1.95 billion, a PE ratio of -116.41 and a beta of 0.58. The company has a debt-to-equity ratio of 1.39, a quick ratio of 1.96 and a current ratio of 2.54. ANI Pharmaceuticals has a one year low of $52.50 and a one year high of $99.50. The stock has a fifty day moving average of $87.95 and a 200 day moving average of $73.16.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, August 8th. The specialty pharmaceutical company reported $1.80 EPS for the quarter, beating analysts’ consensus estimates of $1.42 by $0.38. The company had revenue of $211.37 million during the quarter, compared to analysts’ expectations of $187.18 million. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.ANI Pharmaceuticals’s revenue for the quarter was up 53.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.02 earnings per share. As a group, sell-side analysts predict that ANI Pharmaceuticals will post 3.86 EPS for the current year.

Insider Transactions at ANI Pharmaceuticals

In related news, COO Muthusamy Shanmugam sold 52,990 shares of the stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $87.15, for a total transaction of $4,618,078.50. Following the completion of the transaction, the chief operating officer directly owned 531,920 shares of the company’s stock, valued at approximately $46,356,828. This represents a 9.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jeanne Thoma sold 21,540 shares of the stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $89.15, for a total value of $1,920,291.00. Following the transaction, the director directly owned 23,405 shares of the company’s stock, valued at approximately $2,086,555.75. The trade was a 47.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 413,830 shares of company stock valued at $36,495,294. 11.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Advisors Asset Management Inc. purchased a new position in shares of ANI Pharmaceuticals in the 1st quarter worth approximately $28,000. Caitong International Asset Management Co. Ltd boosted its holdings in shares of ANI Pharmaceuticals by 4,636.4% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company’s stock worth $34,000 after purchasing an additional 510 shares during the period. Newbridge Financial Services Group Inc. boosted its holdings in shares of ANI Pharmaceuticals by 200.0% in the 2nd quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock worth $39,000 after purchasing an additional 400 shares during the period. State of Wyoming purchased a new position in shares of ANI Pharmaceuticals in the 2nd quarter worth approximately $50,000. Finally, National Bank of Canada FI purchased a new position in shares of ANI Pharmaceuticals in the 1st quarter worth approximately $79,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.